iRhythm Technologies, Inc. to Announce Third Quarter 2025 Financial Results on October 30

iRhythm Technologies will announce Q3 2025 financial results on October 30, followed by a conference call.

Quiver AI Summary

iRhythm Technologies, Inc. announced that it will release its third quarter 2025 financial results after the market closes on October 30, 2025. A conference call with the management team will follow at 1:30 p.m. PT / 4:30 p.m. ET, which will be accessible via a live and archived webcast on the company’s investor website. iRhythm is a digital healthcare company specializing in solutions to detect, predict, and prevent disease through wearable biosensors and advanced data analytics. Their goal is to improve patient care by transforming large volumes of heart data into clinically useful insights.

Potential Positives

iRhythm Technologies will provide financial results for Q3 2025, indicating transparency and accountability to investors.
The corresponding conference call will allow direct communication between the company’s management and stakeholders, fostering investor relations.
The release highlights iRhythm's commitment to digital health care and innovative technology, enhancing the company's position in the market.
Providing access to live and archived webcasts demonstrates iRhythm's dedication to keeping investors informed and engaged.

Potential Negatives

Announcement of financial results release may indicate potential concerns about past performance, raising investor scrutiny and uncertainty.
Setting the earnings call for a date far in advance could lead to speculation about whether the company has significant issues to disclose, impacting investor confidence.
No specific financial performance metrics or guidance are provided, which can leave investors and analysts lacking important forward-looking information.

FAQ

When will iRhythm Technologies release its Q3 2025 financial results?

iRhythm Technologies will release its Q3 2025 financial results on October 30, 2025, after market close.

What time is the conference call for iRhythm's Q3 results?

The conference call will begin at 1:30 p.m. PT / 4:30 p.m. ET on October 30, 2025.

How can I access the iRhythm conference call?

Interested parties can access the conference call via a live and archived webcast on the company's investor website.

What is iRhythm Technologies' focus as a digital health care company?

iRhythm focuses on creating trusted solutions that detect, prevent, and predict disease using advanced biosensors and analytics.

Who can I contact for more information about iRhythm?

For investor inquiries, contact Stephanie Zhadkevich; for media inquiries, reach out to Kassandra Perry at Highwire PR.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$IRTC Insider Trading Activity

$IRTC insiders have traded $IRTC stock on the open market 22 times in the past 6 months. Of those trades, 0 have been purchases and 22 have been sales.

Here’s a breakdown of recent trading of $IRTC stock by insiders over the last 6 months:

QUENTIN S. BLACKFORD (President and CEO) has made 0 purchases and 7 sales selling 30,000 shares for an estimated $4,816,191.
CHAD PATTERSON (Chief Commercial Officer) has made 0 purchases and 6 sales selling 15,071 shares for an estimated $2,071,837.
DANIEL G. WILSON (Chief Financial Officer) has made 0 purchases and 3 sales selling 10,000 shares for an estimated $1,575,000.
ABHIJIT Y TALWALKAR has made 0 purchases and 2 sales selling 5,312 shares for an estimated $839,380.
MINANG TURAKHIA (EVP, CMO & CSO) sold 1,420 shares for an estimated $206,482
SUMI SHRISHRIMAL (EVP, Chief Risk Officer) sold 653 shares for an estimated $109,129
MERVIN SMITH (EVP Strategic Business Ops) sold 616 shares for an estimated $101,245
MARC WADE ROSENBAUM (Chief Accounting Officer) sold 226 shares for an estimated $35,918

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$IRTC Hedge Fund Activity

We have seen 167 institutional investors add shares of $IRTC stock to their portfolio, and 117 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CAPITAL RESEARCH GLOBAL INVESTORS removed 695,758 shares (-31.6%) from their portfolio in Q2 2025, for an estimated $107,118,901
MACKENZIE FINANCIAL CORP removed 426,141 shares (-36.9%) from their portfolio in Q2 2025, for an estimated $65,608,668
SLATE PATH CAPITAL LP removed 365,400 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $56,256,984
WESTFIELD CAPITAL MANAGEMENT CO LP removed 326,508 shares (-52.9%) from their portfolio in Q2 2025, for an estimated $50,269,171
HOLOCENE ADVISORS, LP added 298,347 shares (+2023.1%) to their portfolio in Q2 2025, for an estimated $45,933,504
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 295,432 shares (-32.7%) from their portfolio in Q2 2025, for an estimated $45,484,710
MAN GROUP PLC added 267,603 shares (+inf%) to their portfolio in Q2 2025, for an estimated $41,200,157

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$IRTC Analyst Ratings

Wall Street analysts have issued reports on $IRTC in the last several months. We have seen 8 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

BTIG issued a "Buy" rating on 10/13/2025
Baird issued a "Outperform" rating on 10/10/2025
Citigroup issued a "Buy" rating on 10/07/2025
Canaccord Genuity issued a "Buy" rating on 09/29/2025
Needham issued a "Buy" rating on 08/28/2025
Wells Fargo issued a "Overweight" rating on 08/01/2025
JP Morgan issued a "Overweight" rating on 08/01/2025

To track analyst ratings and price targets for $IRTC, check out Quiver Quantitative's $IRTC forecast page.

$IRTC Price Targets

Multiple analysts have issued price targets for $IRTC recently. We have seen 12 analysts offer price targets for $IRTC in the last 6 months, with a median target of $193.0.

Here are some recent targets:

Richard Newitter from Truist Securities set a target price of $205.0 on 10/15/2025
Ryan Zimmerman from BTIG set a target price of $195.0 on 10/13/2025
Mike Polark from Baird set a target price of $220.0 on 10/10/2025
Vijay Kumar from Evercore ISI Group set a target price of $175.0 on 10/07/2025
Joanne Wuensch from Citigroup set a target price of $205.0 on 10/07/2025
David Roman from Goldman Sachs set a target price of $180.0 on 10/01/2025
William Plovanic from Canaccord Genuity set a target price of $193.0 on 09/29/2025

Full Release

SAN FRANCISCO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the third quarter 2025 after the close of trading on Thursday, October 30, 2025. The company’s management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET.

Interested parties may access a live and archived webcast of the conference call on the “Quarterly Results” section of the company’s investor website at investors.irhythmtech.com .

About iRhythm Technologies, Inc.
iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all.

Investor Contact
Stephanie Zhadkevich
[email protected]

Media Contact
Kassandra Perry
[email protected]